Can a higher dose of infliximab tame stubborn rheumatoid arthritis?

NCT ID NCT00691028

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether increasing the dose of infliximab (a drug that blocks inflammation) helps people with active rheumatoid arthritis who did not improve enough with methotrexate alone. 327 adults received one of three doses (3, 6, or 10 mg/kg) by IV infusion over nearly a year. Researchers measured joint pain, swelling, and physical function to see if higher doses worked better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Infliximab (also known as TA-650, Remicade) given by intravenous infusion, plus methotrexate
What this could lead to: If successful, this study could show that a higher dose of infliximab helps control rheumatoid arthritis symptoms better in people who did not get enough relief from methotrexate alone.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all patients. Infliximab can increase the risk of serious infections and allergic reactions. Higher doses may also raise the chance of side effects without adding benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.